Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CYTK – Cytokinetics, Incorporated

Cytokinetics, Incorporated
CYTK
$64.60
Name : Cytokinetics, Incorporated
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,898,314,240.00
EPSttm : -6.3
finviz dynamic chart for CYTK
Cytokinetics, Incorporated
$64.60
5.45%
$3.34

Float Short %

11.13

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

0.01

EPS Last/This Y

-0.83

EPS This/Next Y

0.23

Price

64.56

Target Price

86.61

Analyst Recom

1.43

Performance Q

6.53

Relative Volume

1.27

Beta

0.54

Ticker: CYTK




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-08CYTK64.120.211.08112127
2025-12-09CYTK61.60.210.03112583
2025-12-10CYTK60.340.210.25114495
2025-12-11CYTK60.740.210.38115745
2025-12-12CYTK63.40.200.21116353
2025-12-15CYTK62.190.200.11116441
2025-12-16CYTK620.200.23116791
2025-12-17CYTK59.740.200.56117349
2025-12-18CYTK62.20.210.10118254
2025-12-19CYTK62.720.210.51119818
2025-12-22CYTK65.590.160.15114307
2025-12-23CYTK63.330.170.31115772
2025-12-26CYTK63.070.170.20117369
2025-12-29CYTK61.80.170.10117625
2025-12-30CYTK61.370.170.01117880
2025-12-31CYTK63.550.170.11116387
2026-01-02CYTK61.720.180.17115223
2026-01-05CYTK61.240.180.20116872
2026-01-06CYTK64.570.180.11118141
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-08CYTK64.13-7.2- -5.97
2025-12-09CYTK61.60-7.242.4-5.97
2025-12-10CYTK61.60-7.230.9-5.97
2025-12-11CYTK60.77-7.213.5-5.97
2025-12-12CYTK63.37-7.2-8.5-5.97
2025-12-15CYTK62.16-7.229.6-5.97
2025-12-16CYTK62.16-8.218.0-6.03
2025-12-17CYTK59.78-8.240.3-6.03
2025-12-18CYTK62.26-8.2-8.2-6.03
2025-12-19CYTK62.69-8.213.1-6.03
2025-12-22CYTK66.35-8.2-16.7-6.03
2025-12-23CYTK63.40-9.736.9-6.11
2025-12-26CYTK63.07-7.8148.9-6.13
2025-12-29CYTK61.79-7.8150.7-6.13
2025-12-30CYTK61.36-7.8143.4-6.13
2025-12-31CYTK63.55-7.3122.4-6.09
2026-01-02CYTK61.77-7.3154.2-6.09
2026-01-05CYTK61.24-7.3144.2-6.09
2026-01-06CYTK64.56-7.3112.7-6.09
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-08CYTK-7.743.6612.00
2025-12-09CYTK-7.783.6612.00
2025-12-10CYTK-7.783.6610.80
2025-12-11CYTK-7.783.6610.80
2025-12-12CYTK-7.783.6610.80
2025-12-15CYTK-7.783.6510.80
2025-12-16CYTK-8.083.6510.80
2025-12-17CYTK-7.943.6510.80
2025-12-18CYTK-7.873.6510.80
2025-12-19CYTK-7.873.6510.80
2025-12-22CYTK-7.873.3810.80
2025-12-23CYTK-7.873.3810.80
2025-12-26CYTK-8.593.3811.12
2025-12-29CYTK-8.593.4211.13
2025-12-30CYTK-8.473.4211.13
2025-12-31CYTK-8.533.4211.13
2026-01-02CYTK-8.533.4211.13
2026-01-05CYTK-8.423.4111.13
2026-01-06CYTK-8.903.4111.13
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-1.54

Avg. EPS Est. Current Quarter

-1.35

Avg. EPS Est. Next Quarter

-1.53

Insider Transactions

-8.9

Institutional Transactions

3.41

Beta

0.54

Average Sales Estimate Current Quarter

7

Average Sales Estimate Next Quarter

16

Fair Value

Quality Score

9

Growth Score

44

Sentiment Score

51

Actual DrawDown %

41.4

Max Drawdown 5-Year %

-72.4

Target Price

86.61

P/E

Forward P/E

PEG

P/S

90.57

P/B

P/Free Cash Flow

EPS

-6.31

Average EPS Est. Cur. Y​

-6.09

EPS Next Y. (Est.)

-5.86

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-862.21

Relative Volume

1.27

Return on Equity vs Sector %

117.2

Return on Equity vs Industry %

132.4

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.19

EBIT Estimation

112.7
Cytokinetics, Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 498
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today
news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance
stock history CYTK – Cytokinetics, Incorporated invest stock market
stock prices CYTK premarket after hours
ticker CYTK fair value insiders trading